At ASCB 2015: CRISPR/Cas9 + HPSC = human PKD lab model

December 11, 2015

SAN DIEGO, CA -- CRISPR/Cas9 is hot. News of the revolutionary gene editing technique that is already shaking up bioscience has finally reached the news media and the public. Now comes a first rate example of how CRISPR is changing the pace of biomedical research by linking up with another cutting edge technology -- human pluripotent stem cells (hPSCs). Benjamin S. Freedman, now at the University of Washington, and his colleagues in Joseph Bonventre's lab at Harvard Medical School, have used CRISPR/Cas9 to guide hPSCs into becoming a human cell-based lab model system for polycystic kidney disease (PKD). The most common inherited kidney disorder, affecting one in 500 Americans, PKD currently is not curable and, without long-term dialysis or kidney transplant, can be fatal. Freedman will speak about the PKD model at ASCB 2015 in San Diego on Monday, Dec. 14, 2015, following its earlier publication in Nature Communications.

PKD's hallmark is the formation of damaging, balloon-like cysts in kidney tubules. In the early 2000s, cell biologists linked cyst formation to gene mutations that affect the primary cilia, hair-like projections from cells that seem to act as sensory antennae. These fundamental discoveries were made in non-human organisms such as the algae, Chlamydomonas reinhardtii, and the zebrafish, Danio rerio. But the exact disease mechanism in humans is still not well understood in part because there hasn't been a good human model of PKD in kidney cells.

CRISPR gave Freedman et al. a more precise tool to remodel the hPSC genome to include PKD mutations in the disease-linked genes, PKD1 and PKD2. The researchers then used a 3-D cell culture system to coax their mutant and healthy hPSCs down the differentiation pathway into becoming kidney progenitor cells and finally the proximal tubule cells found in kidney nephrons. In the mutant tubule cells, they observed the formation of large, translucent cyst-like structures but not in their healthy controls. These observations and others have convinced the researchers that their CRISPR/Cas9 and hPSC system produces a stable, biologically accurate human model for a common genetic disease where new understanding and new therapies are desperately needed.
-end-
Modeling Polycystic Kidney Disease Cystogenesis with Genome?Modified Human Pluripotent Stem Cells

B.S. Freedman1,2, T.I. Steinman3, J. Zhou2, J.V. Bonventre2

1Department of Medicine, Division of Nephrology, University of Washington, Seattle, WA

2Department of Medicine, Renal Division, Brigham and Women's Hospital/Harvard Medical School, Boston, MA,

3Department of Medicine, Division of Nephrology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA

Contact Author:
Benjamin S. Freedman
benof@uw.edu
206-685-4653

At ASCB 2015

Author presents:

Microsymposium 8: The Role of the Cytoskeleton in Disease and Repair


E55
Monday, Dec. 14, 2015
12:30-12:35 PM
Microsymposia Room 2 Journal citation: http://www.nature.com/ncomms/2015/151023/ncomms9715/abs/ncomms9715.html

American Society for Cell Biology

Related Polycystic Kidney Disease Articles from Brightsurf:

Pioneering dual surgery a safe option for patients with polycystic kidney disease
Patients with large polycystic kidneys in need of a kidney transplant can have their diseased kidneys safely removed laparoscopically at the same time as their transplant surgery.

Reproducing the pathophysiology of polycystic kidney disease from human iPS cells
A joint research project has successfully reproduced the pathogenesis of autosomal dominant polycystic kidney disease (ADPKD) from human iPS cells in vitro.

Waistline matters in kidney disease
Does fat matter in kidney disease? The investigators found that all measures of higher abdominal fat content (including visceral fat, liver fat, or subcutaneous fat) and slower walk times were associated with increased levels of cardiometabolic risk factors in adults with non-dialysis dependent kidney disease.

Reducing urinary protein for patients with rare kidney disease slows kidney decline
New findings show that reducing the amount of protein in the urine of patients with focal segmental glomerulosclerosis can significantly slow declines in kidney function and extend time before patients' kidneys fail.

Young women with polycystic ovary syndrome have raised risk of heart disease
Women in their 30s and 40s with a common condition affecting how the ovaries work are more likely to get heart disease.

Antioxidant agent may prevent chronic kidney disease and Parkinson's disease
Researchers from Osaka University developed a novel dietary silicon-based antioxidant agent with renoprotective and neuroprotective effects.

Acute kidney injury and end stage kidney disease in severe COVID-19
Many COVID-19 patients experience hematuria, proteinuria and elevated serum creatinine concentration early in the course of the disease.

Should polycystic kidney disease patients be screened for brain aneurysms?
Brain aneurysms were detected by pre-symptomatic screening in 9% of patients with autosomal dominant polycystic kidney disease, more frequently in those with a history of hypertension and smoking.

Is kidney failure a man's disease?
A new analysis of the ERA-EDTA Registry [1] reveals a striking gender difference in the incidence and prevalence of end-stage renal disease.

Chronic kidney disease: Everyone's concern
850 million people worldwide are affected by kidney disease. This worrying figure was published last June.

Read More: Polycystic Kidney Disease News and Polycystic Kidney Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.